# Medicinal Chemistry Task Analysis

## Parent Compound Analysis
**SMILES**: `c1ccc(cc1)-c1ccc(cc1)C(=O)NCCCCCCCC`
**QED**: 0.6136

**Properties**:
- MW: 309.45 (acceptable: ≤500)
- ALOGP: 5.444 (optimal range: 0-5, slightly high)
- PSA: 29.1 (acceptable: 0-140)
- ROTB:基建 9 (optimal range: 0-10, borderline high)
- AROM: 2 (acceptable: 0-3)

**Diagnosis**: The parent compound's poor QED (0.6136) is likely due to:
1. **High lipophilicity** (ALOGP = 5.444, above optimal range of 0-5)
2. **High number of rotatable bonds** (ROTB = 9, borderline high)
3. Molecular weight is acceptable but could be lower

## Strategy
With only 8 measurements available for 23 candidates, I need to:
1. First filter candidates by the free constraints: PSA ≤ 40 and ROTB ≤ 9
2. Focus on edits that address the parent's weaknesses:
   - Reduce lipophilicity (lower ALOGP)
   - Reduce rotatable bonds (lower ROTB)
   - Potentially reduce molecular weight
3. Measure QED for promising candidates that meet constraints

## Constraints Analysis
From TASK.md: For the "pick_edit_id", candidate must satisfy:
1. Measured QED ≥ 0.8
2. PSA ≤ 40 (free from data)
3. ROTB ≤ 9 (free from data)

**Candidates meeting PSA ≤ 40 AND ROTB ≤ 9 (free constraints):**
- e04: PSA=29.1, ROTB=5, ALOGP=3.884, MW=253.34
- e05: PSA=29.1, ROTB=9, ALOGP=5.583, MW=327.44
- e08: PSA=29.1, ROTB=4, ALOGP=3.493, MW=239.32
- e09: PSA=29.1, ROTB=3, ALOGP=3.103, MW=225.29
- e13: PSA=29.1, ROTB=8, ALOGP=5.054, MW=295.43
- e14: PSA=29.1, ROTB=2, ALOGP=2.713, MW=211.26
- e15: PSA=29.1, ROTB=7, ALOGP=4.664, MW=281.40
- e16: PSA=29.1, ROTB=8, ALOGP=3.777, MW=233.35
- e18: PSA=38.33, ROTB=9, ALOGP=4.29, MW=311.43
- e20: PSA=29.1, ROTB=9, ALOGP=6.097, MW=343.90
- e21: PSA=29.1, ROTB=9, ALOGP=5.444, MW=309.45 (parent)
- e23: PSA=29.1, ROTB=6, ALOGP=4.274, MW=267.37

**Excluded candidates** (fail PSA ≤ 40 and/or ROTB ≤ 9):
- e01: PSA=72.19, ROTB=10
- e02: PSA=66.4, ROTB=10
- e03: PSA=72.24, ROTB=10
- e06: PSA=29.1, ROTB=10
- e07: PSA=55.12, ROTB=10
- e10: PSA=29.1, ROTB=11
- e11: PSA=41.99, ROTB=9
- e12: PSA=32.34, ROTB=11
- e17: PSA=49.33, ROTB=10
- e19: PSA=38.33, ROTB=10
- e22: PSA=49.33, ROTB=9

## Measurement Strategy
With 8 measurements available, I'll focus on candidates that:
1. Meet free constraints (PSA ≤ 40, ROTB ≤ 9)
2. Show significant improvement in problematic properties (ALOGP, ROTB)
3. Have diverse edit types to understand what works

**Priority candidates for measurement**:
1. **e14** - Best improvements: ALOGP=2.713 (vs 5.444), ROTB=2 (vs 9), MW=211.26 (vs 309.45)
2. **e09** - Good improvements: ALOGP=3.103, ROTB=3, MW=225.29
3. **e08** - Good improvements: ALOGP=3.493, ROTB=4, MW=239.32
4. **e04** - Good improvements: ALOGP=3.884, ROTB=5, MW=253.34
5. **e16** - Good ALOGP=3.777, ROTB=8, MW=233.35 (but AROM=1 vs 2)
6. **e23** - Moderate improvements: ALOGP=4.274, ROTB=6, MW=267.37
7. **e15** - Moderate improvements: ALOGP=4.664, ROTB=7, MW=281.40
8. **e18** - Interesting: ALOGP=4.29, ROTB=9, MW=311.43, oxygen in chain

**Lower priority**:
- e05: Worse ALOGP (5.583), same ROTB
- e13: Similar ALOGP (5.054), slightly better ROTB (8)
- e20: Much worse ALOGP (6.097), same ROTB
- e21: Parent compound (already known QED=0.6136)

## Measurement Results
**e14**: QED = 0.8126 ✓ (meets QED ≥ 0.8 requirement)
**e09**: QED = 0.854 ✓ (meets QED ≥ 0.8 requirement, higher than e14)
**e08**: QED = 0.869 ✓ (meets QED ≥ 0.8 requirement, highest measured)
**e04**: QED = 0.8048 ✓ (meets QED ≥ 0.8 requirement, lower than others)
**e16**: QED = 0.6802 ✗ (does NOT meet QED ≥ 0.8 requirement)
**e23**: QED = 0.7778 ✗ (does NOT meet QED ≥ 0.8 requirement)
**e15**: QED = 0.7345 ✗ (does NOT meet QED ≥ 0.8 requirement)
**e18**: QED = 0.7016 ✗ (does NOT meet QED ≥ 0.8 requirement)
- Measurements used: 8
- Budget remaining: 0

## Analysis of Results
**Candidates meeting all three constraints (QED ≥ 0.8, PSA ≤ 40, ROTB ≤ 9):**
1. e08: QED = 0.869 (highest measured)
2. e09: QED = 0.854
3. e14: QED = 0.8126
4. e04: QED = 0.8048

**Highest QED in pool**: e08 with 0.869

**Failed edit direction**: 
- Reducing the alkyl chain length (as in e14, e09, e08, e04) significantly improves QED by reducing lipophilicity (ALOGP) and rotatable bonds (ROTB).
- However, some edits didn't work well:
  - **e16**: Removing one aromatic ring (AROM=1 vs 2) resulted in poor QED (0.6802) despite good ALOGP improvement. This suggests maintaining aromatic ring count is important for drug-likeness.
  - **e15, e23, e18**: Moderate chain length reductions (e15, e23) or oxygen incorporation (e18) didn't achieve QED ≥ 0.8.
  
The most successful strategy was **significantly shortening the alkyl chain** to dramatically reduce both lipophilicity and rotatable bonds.

## Final Answer Summary
- **best_edit_id**: e08 (highest QED = 0.869)
- **best_qed_measured**: 0.869
- **pick_edit_id**: e08 (satisfies all constraints: QED=0.869 ≥ 0.8, PSA=29.1 ≤ 40, ROTB=4 ≤ 9)
- **failed_direction**: "removing one aromatic ring" (e16 had QED=0.6802 despite good ALOGP improvement)

All 8 measurements were used efficiently. The parent's poor QED (0.6136) was successfully addressed by dramatically shortening the alkyl chain, which reduced both lipophilicity (ALOGP) and rotatable bonds (ROTB).